Association of β-Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure

Table 3

2-year clinical outcomes of the patients.

	Overall population			AMI subpopulation			UA subpopulation
	Discharged with β-blockers ()	Discharged without β-blockers ()	value	Discharged with β-blockers ()	Discharged without β-blockers ()	value	Discharged with β-blockers ()	Discharged without β-blockers ()	value
Death	47 (0.9)	8 (1.4)	0.317	16 (1.1)	0 (0.0)	0.625	31 (0.9)	8 (1.7)	0.106
Cardiac death	24 (0.5)	3 (0.5)	0.909	10 (0.7)	0 (0.0)	1.000	14 (0.4)	3 (0.6)	0.437
MI	29 (0.6)	5 (0.9)	0.395	8 (0.6)	2 (1.7)	0.167	21 (0.6)	3 (0.6)	0.889
TVR	421 (8.3)	47 (8.0)	0.768	126 (8.7)	9 (7.8)	0.722	295 (8.2)	38 (8.1)	0.913
ST	30 (0.6)	2 (0.3)	0.437	9 (0.6)	0 (0.0)	1.000	21 (0.6)	2 (0.4)	1.000
Stroke	71 (1.4)	8 (1.4)	0.926	14 (1.0)	2 (1.7)	0.336	57 (1.6)	6 (1.3)	0.842
MACCE	538 (10.7)	61 (10.4)	0.827	155 (10.7)	12 (10.3)	1.000	383 (10.6)	49 (10.4)	0.937

Values are presented as (%). ST: stent thrombosis; MACCE: major adverse cardiovascular and cerebrovascular events; MI: myocardial infarction; TVR: unplanned target vessel revascularization.